GOALS OF WORK: Patients with prostate cancer metastasized to bone frequently experience skeletal morbidities as a result of their disease. We sought to quantify the longitudinal effects on patient-reported outcomes of skeletal-related events (SREs) and to ascertain the declines in health-related quality of life (HRQOL) and pain experienced by patients who experienced SREs. MATERIALS AND METHODS: Data are from a clinical trial for the treatment of SREs associated with advanced prostate cancer metastatic to bone. Outcome measures included the Functional Assessment of Cancer Therapy-General (FACT-G) and the Brief Pain Inventory. Among patients who survived 6 months after randomization, patients with no SREs in the initial 6 months after randomization were matched via propensity scores with those experiencing one or more SREs. Similarly, patients with one SRE were matched with a subset of patients with two or more SREs. MAIN RESULTS: Patients with SREs in the initial period had significantly worse survival and HRQOL than those with no SREs. Significant differences were found between the pain differences, FACT-G total scores, and FACT-G physical, emotional, and functional subscales. Comparisons of patients with single vs multiple SREs showed similar patterns. CONCLUSIONS: The presence of SREs is significantly associated with worse survival and poorer HRQOL in this patient population. Increasing SRE intensity shows a pattern of increasingly decreased survival and poorer HRQOL.
GOALS OF WORK: Patients with prostate cancer metastasized to bone frequently experience skeletal morbidities as a result of their disease. We sought to quantify the longitudinal effects on patient-reported outcomes of skeletal-related events (SREs) and to ascertain the declines in health-related quality of life (HRQOL) and pain experienced by patients who experienced SREs. MATERIALS AND METHODS: Data are from a clinical trial for the treatment of SREs associated with advanced prostate cancer metastatic to bone. Outcome measures included the Functional Assessment of Cancer Therapy-General (FACT-G) and the Brief Pain Inventory. Among patients who survived 6 months after randomization, patients with no SREs in the initial 6 months after randomization were matched via propensity scores with those experiencing one or more SREs. Similarly, patients with one SRE were matched with a subset of patients with two or more SREs. MAIN RESULTS: Patients with SREs in the initial period had significantly worse survival and HRQOL than those with no SREs. Significant differences were found between the pain differences, FACT-G total scores, and FACT-G physical, emotional, and functional subscales. Comparisons of patients with single vs multiple SREs showed similar patterns. CONCLUSIONS: The presence of SREs is significantly associated with worse survival and poorer HRQOL in this patient population. Increasing SRE intensity shows a pattern of increasingly decreased survival and poorer HRQOL.
Authors: G N Hortobagyi; R L Theriault; L Porter; D Blayney; A Lipton; C Sinoff; H Wheeler; J F Simeone; J Seaman; R D Knight Journal: N Engl J Med Date: 1996-12-12 Impact factor: 91.245
Authors: L Radbruch; G Loick; P Kiencke; G Lindena; R Sabatowski; S Grond; K A Lehmann; C S Cleeland Journal: J Pain Symptom Manage Date: 1999-09 Impact factor: 3.612
Authors: Kevin P Weinfurt; Liana D Castel; Yun Li; Justin W Timbie; G Alastair Glendenning; Kevin A Schulman Journal: Med Care Date: 2004-02 Impact factor: 2.983
Authors: Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Bee Chen Journal: J Natl Cancer Inst Date: 2002-10-02 Impact factor: 13.506
Authors: N A Janjan; R Payne; T Gillis; D Podoloff; H I Libshitz; R Lenzi; R Theriault; C Martin; A Yasko Journal: J Pain Symptom Manage Date: 1998-09 Impact factor: 3.612
Authors: Juan M Jimenez-Andrade; Aaron P Bloom; James I Stake; William G Mantyh; Reid N Taylor; Katie T Freeman; Joseph R Ghilardi; Michael A Kuskowski; Patrick W Mantyh Journal: J Neurosci Date: 2010-11-03 Impact factor: 6.167
Authors: Zs Küronya; I Sinkovics; P Ágoston; K Bíró; I Bodrogi; I Böde; M Dank; F Gyergyay; T Vajdics; Zs Kolonics; K Nagyiványi; Á Rúzsa; L Géczi Journal: Pathol Oncol Res Date: 2017-01-10 Impact factor: 3.201